Study: NCT04340076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixekizumab
Description: Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brodalumab
Description: Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guselkumab
Description: Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risankizumab
Description: Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tildrakizumab
Description: Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimekizumab
Description: Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.